logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Halozyme: Reading the News While Keeping Our Focus on the Promises

Halozyme Therapeutics (HALO)  seems to have closed the previously announced $150 million royalty-backed debt transaction with investment funds managed by Pharmakon Advisors and Athyrium Capital Management.  The debt is said to be secured by future royalties of ENHANZE™ products, received...

Read More

January 27, 2016

0

Theravance Biopharma: Launching Vibativ in Canada for MRSA

Theravance Biopharma (TBPH)  announced the commercial launch of VIBATIV® (telavancin) in Canada. VIBATIV is a once-daily antibiotic with a dual mechanism of action against Gram-positive bacteria, including difficult-to-treat methicillin-resistant  Staphylococcus aureus  (MRSA). The drug is approved in Canada for adult...

Read More

January 26, 2016

0

Revolutionary Approaches Towards Managing Chronic and Deadly Diseases

The Market is Surely Ignoring the Historical Summit  Biotech achievements are standing on Right Now     The latest biotech sector’s breakthroughs we presented was the novel powerful  gene editing  techniques  CRISPR/cas9  an d TALEN.  Our article in the Prohost...

Read More

January 22, 2016

0

OIL: A Blessing or a Curse? It Depends on What Some Want it to Be

Escaping the slaughter, or taking advantage of it, or  accumulating the stocks we love, or turning from positive to negative investors are all choices on the table. The problem is that the prophets stop prophesizing at times when prophesies are...

Read More

January 20, 2016

0

Exelixis: A Big Yes from the FDA

Based on statistically significant results from the randomized phase 2 CABOSUN trial in patients with previously untreated renal cell carcinoma (RCC), the U.S. Food and Drug Administration (FDA) approved  Exelixis’ (EXEL) drug Cabometyx ®  (cabozantinib) for the expanded indication of patients with...

Read More

December 20, 2017

0

How Far Can the Market Go in Ignoring Gilead?

On Oct. 28, 2015, Gilead Sciences (GILD) announced that it has submitted a New Drug Application (NDA) to the FDA for an investigational, once-daily fixed-dose combination of the approved nucleotide analog polymerase inhibitor sofosbuvir (Sovaldi®) abbreviated as (SOF) and the...

Read More

January 5, 2016

0

Juno and Spark: On the Road Towards Ambitious Goals

Juno Therapeutics (JUNO)  is one of the casualties that occurred during the 59 th  American Society of Hematology (ASH) Annual Meeting. The stock experienced undeserved selloff except for the fact that it had a deserved rally that we believe will remain...

Read More

December 12, 2017

0

Exelixis Has Good News

Exelixis Announces Positive Results from Subgroup Analyses of the METEOR Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma - The results will be Presented at ASCO 2016 Genitourinary Cancers Symposium this month. - Data further highlight clinical...

Read More

January 5, 2016

0

The FDA Accepted Seattle Genetics’ sBLA for Adcetris in Combination with Chemotherapy for Front-Line Treatment of Advanced Classical Hodgkin Lymphoma.

The Food and Drug Administration (FDA) accepted the supplemental Biologics License Application (BLA) for  Seattle Genetics’ (SGEN)  product  Adcetris (brentuximab vedotin)  in combination with chemotherapy for the frontline treatment of patients with  advanced classical Hodgkin lymphoma.  The Agency granted Priority...

Read More

January 2, 2018

0

Steps Forward in the Management of Inflammatory and Autoimmune Diseases

Improving the management of inflammatory and autoimmune diseases has been a dream that seems to be happening slowly but surely in the past years. The improvement has gained energy and speed in 2015. The advancement in treatments has been demonstrated...

Read More

January 8, 2016

0

  • Previous
  • 1
  • 2
  • ...
  • 24
  • 25
  • 26
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy